140 patents
Page 4 of 7
Utility
Enhanced performance verification port for therapeutic gas delivery
21 Dec 21
Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient.
Jaron M. Acker, John C. Falligant, Jeff Milsap, Robin Roehl, Jeffrey Schmidt, Craig R. Tolmie
Filed: 5 Dec 19
Utility
Use and monitoring of inhaled nitric oxide with left ventricular assist devices
21 Dec 21
Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
Jim Potenziano, Douglas Alan Greene, Craig Flanagan
Filed: 30 Jan 17
Utility
Use of Apoptotic Cells Ex Vivo to Generate Regulatory T Cells
16 Dec 21
Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so.
David Peritt, Kim Campbell, Amy Krutsick
Filed: 26 Aug 21
Utility
Method for ex-vivo expansion of regulatory T cells with enhanced suppressive function for clinical application in immune mediated diseases
30 Nov 21
The invention provides methods for the ex-vivo expansion of CD4+CD25+ Tregs.
Tinghua Cao, Li Li
Filed: 16 May 18
Utility
Systems and Methods for High Humidity Curing Within Tablet Coating System
18 Nov 21
The disclosure encompasses systems and methods for performing high temperature and high humidity curing of tablets using air flow delivered from a recirculating air handler to a pan coater of a tablet coating device.
Greg Bengard
Filed: 29 Jul 21
Utility
L-ornithine phenyl acetate and methods of making thereof
2 Nov 21
Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same.
Keith Anderson, Jim Behling, Christine Henderson Dougan, Stephen William Watt, Peter Manini, Attilia Figini
Filed: 31 Jan 20
Utility
Use and Monitoring of Inhaled Nitric Oxide with Left Ventricular Assist Devices
28 Oct 21
Described are systems and methods for administration of nitric oxide (NO) with use of left ventricular assists devices (LVADs), as well as systems and methods for monitoring the NO delivery devices and/or the LVAD.
Jim Potenziano, Douglas Alan Greene, Craig Flanagan
Filed: 25 Jun 21
Utility
Methods to Improve Organ Viability
21 Oct 21
The present disclosure provides methods to improve the viability of an organ, or organs, by continuously administering a composition comprising NOx gas directly to the organ(s).
Jim Potenziano
Filed: 28 Jun 21
Utility
Methods of Modulating Corticosteroid Response
21 Oct 21
The present disclosure is directed to methods of modulating corticosteroid responses in subjects in need thereof.
Dale WRIGHT
Filed: 29 Jun 21
Utility
Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide
12 Oct 21
Described are systems and methods for compensating long term sensitivity drift of catalytic type electrochemical gas sensors used in systems for delivering therapeutic nitric oxide (NO) gas to a patient by compensating for drift that may be specific to the sensors atypical use in systems for delivering therapeutic nitric oxide gas to a patient.
Craig R. Tolmie, Jeff Milsap, Jaron M. Acker
Filed: 29 Jan 16
Utility
(+)-morphinans as antagonists of Toll-like receptor 9 and therapeutic uses thereof
12 Oct 21
The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain.
Bobby N. Trawick
Filed: 3 Feb 20
Utility
Liposomal Elinafide Formulations and Uses Thereof
23 Sep 21
The present invention provides compositions for the treatment of cancer.
William McGHEE, Rick FITCH
Filed: 8 Dec 17
Utility
Method of Treating Patients with Hepatorenal Syndrome Type 1
23 Sep 21
The principles and embodiments of the present disclosure relate to methods for using terlipressin to treat a patient having impaired renal function associated with liver disease.
Khurram Jamil, Stephen Chris Pappas, Peter Teuber
Filed: 7 Jun 21
Utility
Use of apoptotic cells ex vivo to generate regulatory T cells
21 Sep 21
Many cell types in the body can remove apoptotic and cellular debris from tissues; however, the professional phagocyte, or antigen presenting cell (“APC”), has a high capacity to do so.
David Peritt, Kim Campbell, Amy Krutsick
Filed: 19 Oct 18
Utility
Cannula For Minimizing Dilution Of Dosing During Nitric Oxide Delivery
26 Aug 21
Described are nasal cannulas that improve the precision of the delivered dose for nitric oxide therapy by reducing the dilution of nitric oxide.
Craig Flanagan, Simon Freed, John Klaus, Thomas Kohlmann, Martin D. Meglasson, Manesh Naidu, Parag Shah
Filed: 4 May 21
Utility
Extended release, abuse deterrent pharmaceutical compositions
24 Aug 21
Pharmaceutical compositions comprising at least one active pharmaceutical ingredient or a pharmaceutically acceptable salt thereof, at least one hydrophilic plastomer, at least one hydrophilic elastomer, and at least one deliquescent plasticizer, wherein the pharmaceutical compositions provide extended release of the API and have abuse deterrent properties.
Brad L. Gower, Carlos H. Castaneda, Jae Han Park, Clifford J. Herman
Filed: 14 Oct 19
Utility
Systems and methods for intelligent gas source management
17 Aug 21
Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient.
Jaron M. Acker, Craig R. Tolmie, Robin Roehl, Jeffrey Schmidt, Jeff Milsap
Filed: 20 Mar 20
Utility
Systems and methods for high humidity curing within tablet coating system
3 Aug 21
The disclosure encompasses systems and methods for performing high temperature and high humidity curing of tablets using air flow delivered from a recirculating air handler to a pan coater of a tablet coating device.
Greg Bengard
Filed: 23 Aug 19
Utility
Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
20 Jul 21
A pharmaceutical composition comprising at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, a glucomannan, a first polyalkylene oxide having an average molecular weight of no more than 300,000, and a second polyalkylene oxide having an average molecular weight of at least 1,000,000 and methods of making.
Brad L. Gower, Jae Han Park, Clifford J. Herman, Tsz Chung Lai, Kai Feng
Filed: 27 Jan 17
Utility
Gas delivery device and system for use in magnetic resonance imaging
20 Jul 21
The present invention relates to a device and method of delivering inhaled Nitric Oxide (iNO) to a patient situated in a Magnetic Resonance Imaging (MRI) suite.
Craig Flanagan, David Newman, Jaron M. Acker, Craig R. Tolmie, Jim Potenziano
Filed: 12 Dec 18